Read + Share
Fudim M, Van Spall HGC. In HFpEF, the benefit of empagliflozin on a composite of CV death or HF
hospitalization at 26 mo did not vary by diabetes status. Ann Intern Med 2022 Oct 4. doi: 10.7326/J22-0075.
PMID: 36191324
|
 |
|
Fudim M, Van Spall HGC. In HFpEF, the benefit of empagliflozin on a composite of CV death or HF
hospitalization at 26 mo did not vary by diabetes status. Ann Intern Med 2022 Oct 4. doi: 10.7326/J22-0075.
PMID: 36191324
|
|
|
|